Neuraxpharm Allies With Panaxia On Cannabis Portfolio
Launching In Germany, With Other European Countries To Follow
CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.
You may also be interested in...
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.
Perrigo has decided to enter the cannabidiol market in partnership with a known supplier of CBD products, Kazmira. The company has mapped out a two-phased approach for large scale production and supply of cGMP compliant, THC-free CBD.